CN116685326A - Cdk抑制剂的共晶体 - Google Patents

Cdk抑制剂的共晶体 Download PDF

Info

Publication number
CN116685326A
CN116685326A CN202180085401.XA CN202180085401A CN116685326A CN 116685326 A CN116685326 A CN 116685326A CN 202180085401 A CN202180085401 A CN 202180085401A CN 116685326 A CN116685326 A CN 116685326A
Authority
CN
China
Prior art keywords
compound
formula
fumarate
cancer
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180085401.XA
Other languages
English (en)
Chinese (zh)
Inventor
U·布哈特
R·博卡里奥
S·E·巴迪杰
K·德文纳森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurizhen Tumor Co ltd
Original Assignee
Aurizhen Tumor Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurizhen Tumor Co ltd filed Critical Aurizhen Tumor Co ltd
Publication of CN116685326A publication Critical patent/CN116685326A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180085401.XA 2020-12-18 2021-12-17 Cdk抑制剂的共晶体 Pending CN116685326A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18
IN202041055174 2020-12-18
PCT/IB2021/061895 WO2022130304A1 (en) 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor

Publications (1)

Publication Number Publication Date
CN116685326A true CN116685326A (zh) 2023-09-01

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180085401.XA Pending CN116685326A (zh) 2020-12-18 2021-12-17 Cdk抑制剂的共晶体

Country Status (17)

Country Link
US (1) US20240059669A1 (https=)
EP (1) EP4263534A1 (https=)
JP (1) JP2023554492A (https=)
KR (1) KR20230159363A (https=)
CN (1) CN116685326A (https=)
AU (1) AU2021402415A1 (https=)
CA (1) CA3202198A1 (https=)
CL (1) CL2023001753A1 (https=)
CO (1) CO2023009368A2 (https=)
CR (1) CR20230261A (https=)
DO (1) DOP2023000126A (https=)
EC (1) ECSP23054131A (https=)
IL (1) IL303738A (https=)
MX (1) MX2023007218A (https=)
PE (1) PE20231441A1 (https=)
TW (1) TW202241881A (https=)
WO (1) WO2022130304A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118772106A (zh) * 2024-06-07 2024-10-15 山东大学 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022084930A2 (en) * 2020-10-22 2022-04-28 Aurigene Discovery Technologies Limited Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024970A (zh) * 2015-06-04 2018-05-11 奥瑞基尼探索技术有限公司 用作cdk抑制剂的经过取代的杂环衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024970A (zh) * 2015-06-04 2018-05-11 奥瑞基尼探索技术有限公司 用作cdk抑制剂的经过取代的杂环衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RICHARD J.ET AL.: "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 4, no. 5, 19 July 2000 (2000-07-19), pages 427 - 435, XP008154792, DOI: 10.1021/op000018u *
赵浩如: "现代中药制剂新技术", 28 February 2007, 南京：江苏科学技术出版社, pages: 123 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118772106A (zh) * 2024-06-07 2024-10-15 山东大学 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用

Also Published As

Publication number Publication date
CO2023009368A2 (es) 2023-09-29
KR20230159363A (ko) 2023-11-21
ECSP23054131A (es) 2023-09-29
EP4263534A1 (en) 2023-10-25
WO2022130304A1 (en) 2022-06-23
MX2023007218A (es) 2023-07-27
CA3202198A1 (en) 2022-06-23
JP2023554492A (ja) 2023-12-27
US20240059669A1 (en) 2024-02-22
CR20230261A (es) 2023-10-04
IL303738A (en) 2023-08-01
TW202241881A (zh) 2022-11-01
PE20231441A1 (es) 2023-09-14
DOP2023000126A (es) 2023-11-30
AU2021402415A1 (en) 2023-07-06
CL2023001753A1 (es) 2024-02-02

Similar Documents

Publication Publication Date Title
CN116685326A (zh) Cdk抑制剂的共晶体
JP6882299B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
AU2023254980A1 (en) RIP1 inhibitory compounds and methods for making and using the same
TWI765860B (zh) Lsd1抑制劑之鹽
TW202115059A (zh) Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
CN120548318A (zh) Kras g12d抑制剂和其用途
TW201620896A (zh) 苯并咪唑衍生物及其醫藥組合物及使用方法
CN103889984A (zh) 4-(8-甲氧基-1-((1-甲氧基丙烷-2-基)-2-(四氢-2H-吡喃-4-基)-1H-咪唑并[4,5-c]喹啉-7-基)-3,5-二甲基异噁唑及其作为溴结构域抑制剂的用途
AU2015342444A1 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
JP2016528179A (ja) 製造方法及びｍｄｍ２阻害剤の結晶形
CN107163027B (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
CA3018014A1 (en) Naphthyridines as integrin antagonists
CN103459381A (zh) 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸晶型及其生产方法
CN117203208A (zh) 靶向活化与失活态kras g12d的抑制剂
JP2012255038A (ja) 異常な細胞増殖の治療用のピリミジン誘導体
US20230174545A1 (en) Heterocyclic compounds as bet inhibitors
CA3188173A1 (en) Novel compound, and pharmaceutical composition for preventing or treating resistant cancer, comprising same
WO2020064004A1 (zh) 一种mdm2抑制剂，及其制备方法、药物组合物和应用
HK40099717A (zh) Cdk抑制剂的共晶体
EA050691B1 (ru) Сокристалл ингибитора cdk
CN113840605A (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式，及其制备方法和治疗用途
WO2022162604A1 (ko) 카모스타트 및 니클로사마이드를 포함하는 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
TW202543626A (zh) 新穎結晶相形式
TW202404938A (zh) 麩醯胺酸拮抗劑的多晶型及其用途
WO2020222190A1 (en) Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40099717

Country of ref document: HK